Dabur Oncology Plc, a UK-based subsidiary of Dabur India Limited, has signed an exclusive, strategic alliance with Abbott Laboratories, a USD 18 billion US pharma major and one of the largest marketers of injectable pharmaceutical products in the United States.

The alliance will be to develop, manufacture and market prescription generic Oncology products in the United States and will target a number of products that will be developed and marketed on an exclusive long-term basis.

Under terms of agreement, Dabur will provide Abbott with products in finished dosage form and Abbott will market the products in US. A joint management committee comprising of members from both the companies will be formed to manage the alliance.

“Abbott is the industry leader in hospital pharmaceutical products, which is the target segment for Oncology products, and we are excited to join forces with such a large company. This is exactly the kind of collaboration that was envisioned when we set up the Oncology business unit at Dabur," said Dr Anand C Burman, Vice Chairman, Dabur India.

"Dabur has the scientific expertise and the manufacturing skill to get the oncology products to market. The alliance will be strongly positioned to apture significant upsides that are expected in this area. We look forward to working with Abbott in this endeavor," said Ajay Vij, COO, Dabur Pharma.

According to estimates, the global market value of Oncology products losing patent protection by 2010 may exceed $15 billion and the cancer market is expected to see a significant expansion in the number of products losing patent protection over the next decade. "We expect that the joint strengths of this alliance will bring a strong competitive advantage to capture significant share of this attractive market, '' said Vij.

Accenture, which has been engaged by Dabur Pharma in developing and executing its Pharma strategy, assisted Dabur in this deal.